Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway

Gain Therapeutics, Inc.

2023-Q3 EPS reported -$1.42 revenue$55,180

Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.
Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.
Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.
Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.
Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Gain Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $4.7 million, or $0.37 per share basic and diluted, EPS $0.37 per share basic and diluted.

Period: third quarter ended September 30, 2023
Net income: $4.7 million, or $0.37 per share basic and diluted
EPS: $0.37 per share basic and diluted
Result: reported results

Exact text from the filing

On November 14, 2023, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, and business update.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.